TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: bleeding on probing reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: periodontal healing results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in lean mass by DEXA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Improvement in grip strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Morning alertness
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Overall test experience
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Thinning of macular layer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Intracerebral hemorrhagic volumes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of misconceptions about STD-protective behaviors
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Major adverse cardiovascular events (death, MI, or stroke)
Endpoint domain: Mortality/survival
Primary endpoint: Mean serum concentrations of palivizumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 7-year leukemia-free survival (LFS) rate
Endpoint domain: Mortality/survival
Primary endpoint: Erectile function improvement
Endpoint domain: Life impact
Endpoint subdomain: Sexual functioning
Primary endpoint: Positive surgical margins (PSM) rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Mean pain perception
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Technique runtime
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: total fat intake as percentage of calories
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Apgar values at one and five minutes after delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pH values of the umbilical artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Caesarean Intrapartum Rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Increase in peak heart rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Increase in peak oxygen consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in plasma norepinephrine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of brain metastases
Endpoint domain: Mortality/survival
Primary endpoint: Knee adduction moments
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Muscle activation profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: clinical reasoning performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: faster remission after fewer sessions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of exercise echocardiography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Sensitivity of dobutamine echocardiography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Accuracy in predicting coronary disease extent
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: mean number of adverse drug reaction events per patient
Endpoint domain: Adverse events/effects
Primary endpoint: Percent of LIS recipients using generic statins
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Prevalence of severe vitamin D deficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HDL-C levels improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Decline in PINP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Decline in ICTP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in AQLQ score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of repeated ED visits
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Colonic inflammation reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: mean overall discomfort
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Upper extremity use in functional tasks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: speed of motor learning
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: overall amount learnt
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Prevention of asthma-like symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Concentration of MIP-1beta
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Concentration of IL-12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: 4-week continuous abstinence rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of immunological endothelial graft reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Capillary O2 pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: reduction of self-harm and suicide attempts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement of negative mood
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: improvement of general psychiatric symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hard CVD events
Endpoint domain: Mortality/survival
Primary endpoint: HIV-related communication
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Accessed voluntary counseling and testing
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Unprotected sex at last intercourse with a nonspousal partner
Endpoint domain: Adverse events/effects
Primary endpoint: Complete suppression of acute emesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Protection from nausea in the acute phase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of nausea 2 to 24 hours after surgery
Endpoint domain: Adverse events/effects
Primary endpoint: Ratio of complete response 2 to 24 hours after surgery
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of retching 24 to 48 hours after surgery
Endpoint domain: Adverse events/effects
Primary endpoint: placental antioxidant enzyme activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: degree of lipid peroxidation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Confirmed first episode of PCP
Endpoint domain: Mortality/survival
Primary endpoint: Adverse events requiring discontinuation of medication
Endpoint domain: Adverse events/effects
Primary endpoint: Responder rate on CGI
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Score difference on ADAS-cog
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: apparent clearance of abiraterone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: relative bioavailability of abiraterone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: volume of distribution of abiraterone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: family dysfunction characterized by high levels of disengagement
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: oxyhemoglobin saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: lung function (FEV1, peak expiratory flow, MEF, forced inspiratory vital capacity, peak inspiratory flow)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Length of stay 4 days or less or 30-day readmissions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse events in the ward during the first 24 hours
Endpoint domain: Adverse events/effects
Primary endpoint: anterior insula activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: VAS pleasantness ratings of soft touch
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: psychological status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improved survival (life-years gained)
Endpoint domain: Mortality/survival
Primary endpoint: Initial serum creatinine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Response to therapy (resolution of serum creatinine elevations)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Delinquency
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: total satisfaction score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: reward score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: increasing CD4 lymphocyte count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: finding better treatments for patients with HIV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: contribution to society
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Preference for active role in decision-making
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Adequacy of information received about tests and treatments
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Median period of progression-free survival
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Decrease in diastolic blood pressure status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in nighttime pressure load
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: pain medication usage
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Gout concern overall
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Progression-free survival (PRFS)
Endpoint domain: Mortality/survival
Primary endpoint: Bone Scan Index (BSI) progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of concentration above 300 ng/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response in the finger tapping test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference between etCO2 and Paco2 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Total fat and plasma FFA oxidation during exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Alleviation of urinary urgency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Alleviation of urge incontinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Alleviation of stress incontinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Positive rates of type I and type III immunogenicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: incidence of jaundice
Endpoint domain: Adverse events/effects
Primary endpoint: False-negative results
Endpoint domain: Mortality/survival
Primary endpoint: Sensitivity of (18)FDG-PET/CT scan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Unnecessary surgery reduction
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Attendance at PRPs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: episodes of diarrhoea per child-year
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: average cost of illness per episode
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Sustained injury after a hospital fall
Endpoint domain: Adverse events/effects
Primary endpoint: Vo(2peak)% improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Exertional dyspnea (DeltaBorg/DeltaVo(2)) improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: symptom-free condition or improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overall rate of food selection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: radiologic ASD
Endpoint domain: Adverse events/effects
Primary endpoint: Number of blood vessels expressing E-selectin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Number of epidermal Langerhans cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Benefit from dose escalation in intermediate-risk patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lumbar and whole body bone loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Pain scores at postoperative 6 and 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Requests for analgesics during the first postoperative 24 hours
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Tolerability of Preladenant
Endpoint domain: Adverse events/effects
Primary endpoint: ISI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of gastrointestinal symptoms, fever, and chills
Endpoint domain: Adverse events/effects
Primary endpoint: global cognition impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: visuo-spatial attention impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: semantic fluency impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Residual C-peptide secretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anti-GAD titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Exogenous insulin dosages
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete control of vertigo spells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maternal mental health
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Child behavior (perceived sickness)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: School attendance (missed days)
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Low Disease Activity State
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease Activity Score-28-defined remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in Modified Fitzpatrick Wrinkle Scale scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Serum CETP concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: VMO myoelectric activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Gmed myoelectric activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Sample entropy of sEMG signal for erector spinae
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Proportion of patients with osteoporosis/osteopenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Improvement of PEA odor threshold levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global eating disorder symptoms at end of treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of objective binge-eating episodes at end of treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visible haematomas
Endpoint domain: Adverse events/effects
Primary endpoint: Patient satisfaction with relief of preoperative symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 3-year event free rate
Endpoint domain: Mortality/survival
Primary endpoint: Average daily glucose concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improvement in six minute walk distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in management based on imaging results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Stress reactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: days with compulsory admission
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: nonsuicidal self‐injuries
Endpoint domain: Adverse events/effects
Primary endpoint: mobility domain of daily life functioning
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Reduction in mean VPI scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Body satisfaction scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: cardiovascular safety profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: color clearance of urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bioequivalence of memantine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic concordance of 4SLHBT with standard LHBT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of 4SLHBT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of 4SLHBT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median BE surface regression at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TOHEX
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: NOVIS
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: OPEX
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Dp‐ucMGP concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Osteocalcin ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Risk of dementia or MCI
Endpoint domain: Mortality/survival
Primary endpoint: Poor ovarian response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Minutes/week of moderate to vigorous physical activity (PA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Compliance with aerobic PA recommendations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Generalized seizures
Endpoint domain: Adverse events/effects
Primary endpoint: Persistent pain at one month
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need of Ketamine
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Duration of stay after procedure
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Patient preferences
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: VEGF synthesis levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: b-FGF synthesis levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of circulatory disturbances in CRVO
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percent symptom-free days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: virological success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Short Form-8 mental component score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: VT/VF/death
Endpoint domain: Mortality/survival
Primary endpoint: VT/VF
Endpoint domain: Mortality/survival
Primary endpoint: Acid-suppressing effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mean log CFU of Gram (+) bacteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Species number increase in infants weighing less than 1500 g
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes